Zogenix Inc. Daily Stock Analysis

Daily Stock Analysis, ZGNX, Zogenix Inc, priceseries

Zogenix Inc. Daily Stock Analysis
Stock Information
Open
26.60
Close
26.68
High
26.90
Low
26.51
Previous Close
26.26
Daily Price Gain
0.42
YTD High
26.90
YTD High Date
Mar 4, 2022
YTD Low
15.12
YTD Low Date
Jan 13, 2022
YTD Price Change
9.39
YTD Gain
54.31%
52 Week High
26.90
52 Week High Date
Mar 4, 2022
52 Week Low
11.03
52 Week Low Date
Nov 30, 2021
52 Week Price Change
6.81
52 Week Gain
34.27%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 13. 2017
9.55
Mar 2. 2017
10.29
12 Trading Days
7.76%
Link
LONG
May 4. 2017
11.15
May 23. 2017
12.83
13 Trading Days
15.07%
Link
LONG
Jun 2. 2017
13.55
Jun 27. 2017
14.44
17 Trading Days
6.59%
Link
LONG
Sep 1. 2017
12.20
Sep 14. 2017
14.18
8 Trading Days
16.20%
Link
LONG
Sep 29. 2017
35.05
Oct 23. 2017
38.41
16 Trading Days
9.59%
Link
LONG
Feb 14. 2018
38.95
Feb 28. 2018
42.43
9 Trading Days
8.93%
Link
LONG
May 15. 2018
39.35
Jun 22. 2018
45.41
27 Trading Days
15.39%
Link
LONG
Jul 11. 2018
46.30
Jul 27. 2018
57.39
12 Trading Days
23.96%
Link
LONG
Jan 2. 2019
38.15
Jan 16. 2019
42.57
10 Trading Days
11.60%
Link
LONG
Jan 30. 2019
42.45
Mar 6. 2019
51.10
24 Trading Days
20.38%
Link
LONG
Oct 11. 2019
41.04
Nov 4. 2019
44.45
16 Trading Days
8.30%
Link
LONG
Dec 10. 2019
47.18
Dec 27. 2019
51.70
12 Trading Days
9.59%
Link
LONG
May 15. 2020
27.60
May 28. 2020
29.15
8 Trading Days
5.60%
Link
LONG
Oct 13. 2020
18.80
Nov 2. 2020
20.30
14 Trading Days
7.99%
Link
LONG
Dec 15. 2021
13.32
Jan 5. 2022
16.19
14 Trading Days
21.55%
Link
Company Information
Stock Symbol
ZGNX
Exchange
NasdaqGM
Company URL
http://www.zogenix.com
Company Phone
(510) 550-8300
CEO
Stephen J. Farr
Headquarters
California
Business Address
5858 HORTON STREET, #455, EMERYVILLE, CA 94608
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001375151
About

Zogenix, Inc. is a pharmaceutical company, which engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. It develops two products candidate: ZX008 and Relday. The company was founded by Stephen J. Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.

Description

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. The company's lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. It also develops Relday, an injectable formulation of risperidone to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading